GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » 5-Year Yield-on-Cost %

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) 5-Year Yield-on-Cost % : 0.00 (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition 5-Year Yield-on-Cost %?

Eucrates Biomedical Acquisition's yield on cost for the quarter that ended in Dec. 2022 was 0.00.


The historical rank and industry rank for Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost % or its related term are showing as below:



EUCRU's 5-Year Yield-on-Cost % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.96
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost % falls into.



Eucrates Biomedical Acquisition 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Eucrates Biomedical Acquisition is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Eucrates Biomedical Acquisition  (NAS:EUCRU) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Eucrates Biomedical Acquisition 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines